Search
fibrinogen concentrate (RiaSTAP)
Indications:
- treatment of bleeding in congenital fibrinogen deficiency, including afibrinogenemia & hypofibrinogenemia
Contraindications:
- not indicated for dysfibrinogenemia
Dosage:
- intravenous infusion
- Dose (mg/kg body weight) =
[Target level (mg/dL) - measured level (mg/dL)]
-----------------------------------------------
1.7 (mg/dL per mg/kg body weight)
- Dose when fibrinogen level is unknown: 70 mg/kg body weight
- monitoring of fibrinogen level is recommended
- target fibrinogen level of 100 mg/dL should be maintained until hemostasis is achieved
- infusion rate should not exceed 5 mL per minute
Single-use vial containing 900-1300 mg of lyophilized powder for reconstitution
Adverse effects:
1) most serious adverse effects
a) thromboembolism
1] pulmonary embolism
2] myocardial infarction
3] deep vein thrombosis
b) anaphylactic reactions
2) most common adverse reactions (>1%)
a) fever
b) headache
Mechanism of action:
- human fibrinogen concentrate
General
fibrinogen; coagulation factor-1
hematologic agent
References
- Prescriber's Letter 17(2): 2010
New Drugs Approved by the FDA in 2009
Detail-Document#: 260213
(subscription needed) http://www.prescribersletter.com
- Medical Knowledge Self Assessment Program (MKSAP) 17, 18.
American College of Physicians, Philadelphia 2015, 2018